Karyopharm Therapeutics (KPTI) Payables (2012 - 2026)

Karyopharm Therapeutics (KPTI) has reported Payables for 15 consecutive years, with $7.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Payables rose 194.96% year-over-year to $7.7 million; the trailing twelve-month figure through Jun 2026 stood at $7.7 million (up 194.96% YoY), and the FY2025 full-year result was $4.0 million, down 21.62% from the prior year.
• Payables improved to $7.7 million in Q2 2026 per KPTI's latest filing, from $4.0 million in the prior quarter.
• Across five years, Payables topped out at $9.0 million in Q1 2023 and bottomed at $813000.0 in Q3 2022.
• Historically, Payables has averaged $4.0 million across 5 years, with a median of $3.4 million in 2022.
• The widest YoY moves for Payables: up 513.26% in 2024, down 44.41% in 2024.
• Over 5 years, Payables stood at $2.8 million in 2022, then rose by 12.62% to $3.1 million in 2023, then surged by 63.53% to $5.1 million in 2024, then slipped by 21.62% to $4.0 million in 2025, then jumped by 91.36% to $7.7 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $7.7 million, $4.0 million, and $5.4 million for Q2 2026, Q4 2025, and Q3 2025 respectively.